FDA approves first drug designed to treat hot flashes

In May 2023, the FDA approved fezolinetant (Veozah), a nonhormonal drug specifically designed to reduce the frequency and severity of hot flashes in women. Potential side effects include liver damage, abdominal pain, diarrhea, insomnia, or back pain.